MicroTransponder, Inc., a Dallas, Texas-based medical device company which is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications, has raised $7m in a Series B round of funding.
In addition, the company has been awarded a $2.6m NINDS SBIR FastTrack U44 grant, which is a milestone-driven cooperative agreement to support pre-clinical validation of devices for the treatment of neuropathic pain and manufacturing scale-up.
This funding has allowed the company to hire premier clinical and regulatory expertise and to prepare a series of clinical trials and regulatory filings on their initial product, the SAINT™ System for chronic pain.
MicroTransponder is adding Dr. Evan Rosenfeld, who will serve as Chief Medical Officer and Vice President of Regulatory Affairs, and Brent Tarver, who will serve as Vice President of Clinical Affairs.
FinSMEs
24/02/2010